-
1دورية أكاديمية
المؤلفون: Ruolin Liu, Yingxin Wu, Jin Gong, Rui Zhao, Li Li, Qianyi Wan, Nan Lian, Xiaoding Shen, Lin Xia, Yuhou Shen, Haitao Xiao, Xiaoting Wu, Yi Chen, Ying Cen, Xuewen Xu
المصدر: Cancer Medicine, Vol 11, Iss 16, Pp 3093-3105 (2022)
مصطلحات موضوعية: adjuvant imatinib, gastrointestinal stromal tumors, high risk, individualized treatment duration, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/2045-7634Test
-
2دورية أكاديمية
المؤلفون: ESMO Guidelines Comm, EURACAN, GENTURIS, Casali, P. G., Blay, J. Y., Abecassis, N., Joensuu, H., Morosi, C.
المساهمون: Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, Department of Oncology, Clinicum, University of Helsinki
مصطلحات موضوعية: GIST, clinical practice guidelines, gastrointestinal stromal tumour, surgery, tyrosine kinase inhibitor, PHASE-II TRIAL, NEOADJUVANT/ADJUVANT IMATINIB MESYLATE, ADJUVANT IMATINIB, SOFT-TISSUE, EMISSION-TOMOGRAPHY, CARNEY-STRATAKIS, RANDOMIZED-TRIAL, NATURAL-HISTORY, TYROSINE KINASE, DOSE IMATINIB, 3122 Cancers
وصف الملف: application/pdf
العلاقة: We acknowledge patient representatives Gerard van Oortmerssen and Marcus Wartenburg from Sarcoma Patients EuroNet (SPAEN), who attended the consensus meeting as observers and contributed the valuable perspectives of patients to the consensus process. The authors thank Louise Green and Richard Lutz of the ESMO Guidelines staff for their support throughout the whole consensus process and Jackie Jones of JJ Medical Communications Ltd for her project management support during the virtual consensus meeting. This support was funded by ESMO. Manuscript editing support was provided by Louise Green and Catherine Evans (ESMO Guidelines staff). Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and preparation of the ESMO-MCBS table. Dr Joaquin Mateo (Chair of the ESMO Translational Research and Precision Medicine Working Group) provided validation support for integration of ESCAT scores into this guideline. Dr Svetlana Jezdic (ESMO Medical Affairs Advisor) provided coordination and support of the ESCAT scores and their presentation in the table.; ESMO Guidelines Comm , ESMO Guidelines Comm , EURACAN , GENTURIS , Casali , P G , Blay , J Y , Abecassis , N , Joensuu , H & Morosi , C 2022 , ' Gastrointestinal stromal tumours : ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 33 , no. 1 , pp. 20-33 . https://doi.org/10.1016/j.annonc.2021.09.005Test; ORCID: /0000-0003-0281-2507/work/105907538; a4dfae4f-b7fd-4cb4-b0d7-1d23418a61ac; http://hdl.handle.net/10138/568962Test; 000731865200006
-
3دورية أكاديمية
المؤلفون: Incorvaia, Lorena, De Biase, Dario, Nannini, Margherita, Fumagalli, Elena, Vincenzi, Bruno, De Luca, Ida, Brando, Chiara, Perez, Alessandro, Pantaleo, Maria A, Gasperoni, Silvia, D'Ambrosio, Lorenzo, Grignani, Giovanni, Maloberti, Thais, Pedone, Erika, Bazan Russo, Tancredi Didier, Mazzocca, Alessandro, Algeri, Laura, Dimino, Alessandra, Barraco, Nadia, Serino, Roberta, Gristina, Valerio, Galvano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe
المساهمون: Incorvaia, Lorena, De Biase, Dario, Nannini, Margherita, Fumagalli, Elena, Vincenzi, Bruno, De Luca, Ida, Brando, Chiara, Perez, Alessandro, Pantaleo, Maria A, Gasperoni, Silvia, D'Ambrosio, Lorenzo, Grignani, Giovanni, Maloberti, Thai, Pedone, Erika, Bazan Russo, Tancredi Didier, Mazzocca, Alessandro, Algeri, Laura, Dimino, Alessandra, Barraco, Nadia, Serino, Roberta, Gristina, Valerio, Galvano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe
مصطلحات موضوعية: KIT mutation, PDGFRA mutation, GIST, adjuvant imatinib, variant allele frequency
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37463014; volume:Jul 18; firstpage:1; lastpage:11; numberofpages:11; journal:THE ONCOLOGIST; https://hdl.handle.net/2318/1923650Test
-
4دورية أكاديمية
المؤلفون: Lorena Incorvaia, Dario De Biase, Margherita Nannini, Elena Fumagalli, Bruno Vincenzi, Ida De Luca, Chiara Brando, Alessandro Perez, Maria A Pantaleo, Silvia Gasperoni, Lorenzo D'Ambrosio, Giovanni Grignani 8, Thais Maloberti, Erika Pedone, Tancredi Didier Bazan Russo, Alessandro Mazzocca, Laura Algeri, Alessandra Dimino, Nadia Barraco, Roberta Serino, Valerio Gristina, Antonio Galvano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti
المساهمون: Lorena Incorvaia, Dario De Biase, Margherita Nannini, Elena Fumagalli, Bruno Vincenzi, Ida De Luca, Chiara Brando, Alessandro Perez, Maria A Pantaleo, Silvia Gasperoni, Lorenzo D'Ambrosio, Giovanni Grignani 8, Thais Maloberti, Erika Pedone, Tancredi Didier Bazan Russo, Alessandro Mazzocca, Laura Algeri, Alessandra Dimino, Nadia Barraco, Roberta Serino, Valerio Gristina, Antonio Galvano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti
مصطلحات موضوعية: KIT mutation, PDGFRA mutation, GIST, adjuvant imatinib, variant allele frequency
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001030635200001; volume:18; firstpage:1; lastpage:11; numberofpages:11; journal:THE ONCOLOGIST; https://hdl.handle.net/11585/936793Test
-
5دورية أكاديمية
المؤلفون: Brinch, Charlotte Margareta, Aggerholm-Pedersen, Ninna, Hogdall, Estrid, Krarup-Hansen, Anders
المصدر: Brinch , C M , Aggerholm-Pedersen , N , Hogdall , E & Krarup-Hansen , A 2022 , ' Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review ' , Critical Reviews in Oncology/Hematology , vol. 172 , 103650 . https://doi.org/10.1016/j.critrevonc.2022.103650Test
مصطلحات موضوعية: Gastrointestinal stromal tumor, Neoadjuvant treatment, Adjuvant treatment, Life-long treatment, Medical oncological treatment, Treatment effect, ADJUVANT IMATINIB MESYLATE, PHASE-II TRIAL, POSITRON-EMISSION-TOMOGRAPHY, TYROSINE KINASE INHIBITOR, ENDOTHELIAL GROWTH-FACTOR, ITALIAN SARCOMA GROUP, SOFT-TISSUE SARCOMAS, EUROPEAN ORGANIZATION, OPEN-LABEL, HIGH-RISK
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.critrevonc.2022.103650Test
https://pure.au.dk/portal/da/publications/medical-oncological-treatment-for-patients-with-gastrointestinal-stromal-tumour-gist--a-systematic-reviewTest(d4715ea8-567f-436f-a310-605a40e98cfb).html
https://pure.au.dk/ws/files/339866571/1-s2.0-S1040842822000749-main.pdfTest
http://www.scopus.com/inward/record.url?scp=85126338434&partnerID=8YFLogxKTest -
6دورية أكاديمية
المصدر: Cost Effectiveness and Resource Allocation, Vol 17, Iss 1, Pp 1-12 (2019)
مصطلحات موضوعية: Cost-utility analysis, Adjuvant imatinib, Recurrence, Gastrointestinal stromal tumour, GIST, Medicine (General), R5-920
وصف الملف: electronic resource
العلاقة: http://link.springer.com/article/10.1186/s12962-018-0169-9Test; https://doaj.org/toc/1478-7547Test
-
7دورية أكاديمية
المؤلفون: Steeghs, Elisabeth M. P., Gelderblom, Hans, Ho, Vincent K. Y., Voorham, Quirinus J. M., Willems, Stefan M., Grunberg, Katrien, Ligtenberg, Marjolijn J. L.
المصدر: PATH consortium , Steeghs , E M P , Gelderblom , H , Ho , V K Y , Voorham , Q J M , Willems , S M , Grunberg , K & Ligtenberg , M J L 2021 , ' Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice ' , Gastric cancer , vol. 24 , no. 5 , pp. 990-1002 . https://doi.org/10.1007/s10120-021-01190-9Test
مصطلحات موضوعية: Gastrointestinal stromal tumor, Predictive genetic testing, Imatinib, Molecular targeted therapy, Guidelines, KIT, PDGFRA, ADJUVANT IMATINIB MESYLATE, OF-FUNCTION MUTATIONS, PDGFRA MUTATIONS, TYROSINE KINASE, KIT MUTATIONS, C-KIT, REGISTRY, RISK, GIST, RECURRENCE
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1007/s10120-021-01190-9Test
https://hdl.handle.net/11370/64cfe928-c839-4426-831f-7d763ae0f557Test
https://research.rug.nl/en/publications/64cfe928-c839-4426-831f-7d763ae0f557Test
https://pure.rug.nl/ws/files/170833868/Nationwide_evaluation_of_mutation_tailored_treatment_of_gastrointestinal_stromal_tumors_in_daily_clinical_practice.pdfTest -
8دورية أكاديمية
المؤلفون: ESMO Guidelines Comm EURACAN, Casali, P. G., Joensuu, H.
المساهمون: Heikki Joensuu / Principal Investigator, Department of Oncology, Clinicum, HUS Comprehensive Cancer Center
مصطلحات موضوعية: PHASE-II TRIAL, NEOADJUVANT/ADJUVANT IMATINIB MESYLATE, ADJUVANT IMATINIB, RANDOMIZED-TRIAL, CARNEY-STRATAKIS, DOSE IMATINIB, GIST, MUTATIONS, SURGERY, KIT, 3122 Cancers, 3121 General medicine, internal medicine and other clinical medicine
وصف الملف: application/pdf
العلاقة: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker's honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has received research funds from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Amgen and has reported advisory roles for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma, Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has reported honoraria from Roche and PharmaMar and advisory board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting advisory role for PharmaMar, Lilly, Bayer, Novartis and being a member of the speaker's bureau for PharmaMar and received travel grants from PharmaMar and Lilly; APDT is a member of the speakers' bureau for Lilly, Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Nanobiotix, and research funds from PharmaMar and travel grants from PhramaMar and Nanobiotix; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE healthcare and Philips, he has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Novartis, Pfizer and Bayer and advisory role for Bayer; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and; ESMO Guidelines Comm EURACAN , Casali , P G & Joensuu , H 2018 , ' Gastrointestinal stromal tumours : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 29 , no. Suppl 4 , pp. 68-78 . https://doi.org/10.1093/annonc/mdy095Test; ORCID: /0000-0003-0281-2507/work/50558706; 85054214404; ddbe34a2-336d-4f8b-af16-5bb5005e1ab2; http://hdl.handle.net/10138/306617Test; 000448047900006
-
9دورية أكاديمية
المؤلفون: Kang, Yoon-Koo, Kang, Byung Woog, Im, Seock-Ah, Lee, Jae-Lyun, Park, Sook Ryun, Kang, Won Ki, Chang, Heung Moon, Kim, Tae Won, Oh, Do-Youn, Jung, Kyung Hae, Ryu, Min-Hee
المساهمون: 임석아, Im, Seock-Ah, Oh, Do-Youn
مصطلحات موضوعية: GASTROINTESTINAL STROMAL TUMORS, C-KIT, TYROSINE KINASE, PROGNOSIS, INHIBITOR, DELETIONS, Gastrointestinal stromal tumor, Adjuvant imatinib mesylate, KIT exon 11 mutation, High risk
العلاقة: Cancer Chemotherapy and Pharmacology, Vol.71 No.1, pp.43-51; 106635; https://hdl.handle.net/10371/177345Test; 000313004900006; 2-s2.0-84872338974
-
10دورية أكاديمية
المؤلفون: Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., Buonadonna, A., De Alava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A. M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R. L., Hannu, A., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R. L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krakorova, D. A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M. A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A. L., Reichardt, P., Robinson, M. H., Rutkowski, P., Safwat, A. A., Schoffski, P., Sleijfer, S., Stacchiotti, S., Hall, K. Sundby, Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., Blay, J. Y., ESMO Guidelines Comm EURACAN
المساهمون: Casali, P. G. Fdn IRCCS Ist Nazl Tumori, Milan, Italy, Frezza, A. M. Fdn IRCCS Ist Nazl Tumori, Milan, Italy, Gronchi, A. Fdn IRCCS Ist Nazl Tumori, Milan, Italy, Casali, P. G. Univ Milan, Milan, Italy, Frezza, A. M. Univ Milan, Milan, Italy, Gronchi, A. Univ Milan, Milan, Italy, Abecassis, N. EPE, Inst Portugues Oncol Lisboa Francisco Gentil, Lisbon, Portugal, Bauer, S. Univ Hosp Essen, Essen, Germany, Biagini, R. Regina Elena Inst Canc Res, IFO, Musculoskeletal Tissue Bank, Dept Oncol Orthoped, Rome, Italy, Bielack, S. Olga Hosp, Klinikum Stuttgart, Stuttgart, Germany, Bonvalot, S. Inst Curie, Paris, France, Piperno-Neumann, S. Inst Curie, Paris, France, Boukovinas, I. NORDIX, Athens, Greece, Bovee, J. V. M. G. Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands, Brodowicz, T. Med Univ Wien, Vienna Gen Hosp AKH, Vienna, Austria, Broto, J. M. Hosp Univ Virgen Rocio, CIBERONC, Seville, Spain, De Alava, E. Hosp Univ Virgen Rocio, CIBERONC, Seville, Spain, Buonadonna, A. Ctr Riferimento Oncol Aviano, Aviano, Italy, Dei Tos, A. P. Osped Reg Treviso S Maria Ca Foncello, Treviso, Italy, Del Muro, X. G. HUB, ICO Hosp, Integrated Unit, Barcelona, Spain, Dileo, P. Univ Coll London Hosp, Sarcoma Unit, London, England, Eriksson, M. Skane Univ Hosp Lund, Lund, Sweden, Fedenko, A. NN Blokhin Russian Canc Res Ctr, Moscow, Russia, Ferraresi, V. Inst Sci Hosp Care, Regina Elena Natl Canc Inst, IRCCS, Rome, Italy, Ferrari, A. Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy, Ferrari, S. Ist Ortoped Rizzoli, Bologna, Italy, Picci, P. Ist Ortoped Rizzoli, Bologna, Italy, Gasperoni, S. Univ Careggi Firenze, Azienda Osped, Florence, Italy, Gelderblom, H. Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands, Gil, T. Inst Jules Bordet, Brussels, Belgium, Grignani, G. IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy, Haas, R. L. Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands, Haas, R. L. Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands, Hannu, A. Turku Univ Hosp, Turun Yliopistollinen Keskussairaala, Turlu, Finland, Hassan, B. Oxford Univ Hosp NHS Fdn Trust, Oxford, England, Hohenberger, P. Mannheim Univ, Med Ctr, Mannheim, Germany, Kasper, B. Mannheim Univ, Med Ctr, Mannheim, Germany, Issels, R. Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany, Joensuu, H. Univ Helsinki, Cent Hosp, HUCH, Helsinki, Finland, Jones, R. L. Royal Marsden Hosp, London, England, Van der Graaf, W. Royal Marsden Hosp, London, England, Judson, I. Inst Canc Res, London, England, Jutte, P. Univ Med Ctr Groningen, Groningen, Netherlands, Kaal, S. Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands, Kopeckova, K. Univ Hosp Motol, Prague, Czech Republic, Krakorova, D. A. Masaryk Mem Canc Inst, Brno, Czech Republic, Le Cesne, A. Gustave Roussy Canc Campus, Villejuif, France, Lugowska, I. Marie Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland, Rutkowski, P. Marie Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland, Merimsky, O. Tel Aviv Sourasky Med Ctr Ichilov, Tel Aviv, Israel, Montemurro, M. Univ Hosp Lausanne, Med Oncol, Lausanne, Switzerland, Pantaleo, M. A. Univ Bologna, Policlin S Orsola Malpighi, Azienda Osped, Bologna, Italy, Piana, R. Univ Cita Salute & Sci Torino, Azienda Osped, Turin, Italy, Pousa, A. L. Hosp Santa Creu & Sant Pau, Fundacio Gestio Sanitaria, Barcelona, Spain, Reichardt, P. Helios Klinikum Berlin Buch, Berlin, Germany, Robinson, M. H. Weston Pk Hosp NHS Trust, Dept Clin Oncol, YCRC, Sheffield, S Yorkshire, England, Safwat, A. A. Aarhus Univ Hosp, Aarhus, Denmark, Schoffski, P. Leuven Canc Inst, Leuven, Belgium, Sleijfer, S. Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands, Stacchiotti, S. Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy, Hall, K. Sundby Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway, Unk, M. Inst Oncol Ljubljana, Ljubljana, Slovenia, Van Coevorden, F. Netherlands Canc Inst Antoni van Leeuwenhoek, Amsterdam, Netherlands, Whelan, J. Univ Coll Hosp, London, England, Wardelmann, E. Univ Klinikum Munster, Gerhard Domagk Inst Pathol, Munster, Germany, Zaikova, O. Norwegian Radium Hosp, Oslo Univ Hosp, Oslo, Norway, Blay, J. Y. Ctr Leon Bernard, Lyon, France, Blay, J. Y. UCBL1, Lyon, France, Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar, Incyte, Lilly, Bayer, Janssen-Cilag, Eisai, Loxo Oncology, Nanobiotix, Bristol-Myers Squibb, Merck Sharp Dohme, Roche, Amgen, EuroSarc, CoBioRes, Exelixis, Plexxikon, Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Boehringer Ingelheim, Cristal Therapeutics, Daichii Sankyo Pharma
مصطلحات موضوعية: Phase-ii trial, Neoadjuvant/adjuvant imatinib mesylate, Adjuvant imatinib, Carney-stratakis, Dose imatinib, Gist, Mutations, Surgery, Progression, Recurrence
العلاقة: http://hdl.handle.net/10668/18935Test; http://www.annalsofoncology.org/article/S0923753419316916/pdfTest; 448047900006
الإتاحة: https://doi.org/10.1093/annonc/mdy095Test
http://hdl.handle.net/10668/18935Test
http://www.annalsofoncology.org/article/S0923753419316916/pdfTest
النص الكامل